Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Go back to Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)| Merck & Co. (NYSE: MRK) | Delayed: 153.10 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $153.10 | 52 Week High | $65.46 | |||
| Open | $153.10 | 52 Week Low | $47.97 | |||
| Day High | $153.10 | P/E | 104.15 | |||
| Day Low | $153.10 | EPS | $1.47 | |||
| Volume | 48,838 | |||||
